Frontiers in Medicine (Jun 2024)

Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients

  • Wenjuan Zhao,
  • Yi Liu,
  • Mengdi Zhang,
  • Zixin Cui,
  • Zhan Qu,
  • Yiyang Li,
  • Meijuan Wan,
  • Wen Wang,
  • Yunru Chen,
  • Lei Shi,
  • Jianzhou Li,
  • Feng Ye

DOI
https://doi.org/10.3389/fmed.2024.1399665
Journal volume & issue
Vol. 11

Abstract

Read online

BackgroundThis study was aimed at investigating the dynamics of lipids and the effect of TAF on the lipid profile of patients including fatty liver disease in CHB patients.MethodsThe data of TC, LDL-c, HDL-c, TG, and TC/HDL ratio were collected at baseline, 24 weeks, 48 weeks, 72 weeks, and 96 weeks. CHB patients with fatty liver at baseline were further analyzed in a subgroup.ResultsA total of 137 CHB patients treated with TAF were enrolled in this study. During 96 weeks of TAF treatment, there was no significant change in TC, LDL-c, HDL-c, and TG level (P > 0.05). The TC/HDL-c ratio was increased with no significant change (+0.24, P > 0.05). In CHB patients with fatty liver (n = 48), TC, LDL-c, and TC/HDL-c ratio increased gradually during TAF treatment, TG levels increased to 146.63 mg/dL at 48 weeks (P = 0.057) and then decreased, but there was still no significant change compared with the baseline level by 96 weeks (P > 0.05).ConclusionTAF treatment had a low effect on the lipid profile of CHB patients over the course of 96 weeks, and it was safe even in patients with fatty liver.Clinical trial registration[https://www.chictr.org.cn/showproj.html?proj=65123], identifier [ChiCTR2000041005].

Keywords